From TGF-β to Cancer Therapy
Journal:
Current Drug Targets
Volume:
4
Page:
243-250
Author(s):
Xuemei Huang and Chung Lee
Survivin: Role in Normal Cells and in Pathological Conditions
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
131-152
Author(s):
L. O'Driscoll, R. Linehan and M. Clynes
Cyclin-Dependent Kinase Inhibitors: Cancer Killers to Neuronal Guardians
Journal:
Current Medicinal Chemistry
Volume:
10
Page:
367-379
Author(s):
E. A. Monaco III and M. L. Vallano
Heparin Derivatives as Angiogenesis Inhibitors
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
553-566
Author(s):
M. Presta, D. Leali, H. Stabile, R. Ronca, M. Camozzi, L. Coco, E. Moroni, S. Liekens and M. Rusnati
Genetic Polymorphism and Tumor Immunotherapy
Journal:
Current Pharmacogenomics
Volume:
1
Page:
37-57
Author(s):
Rongcun Yang and Richard B.S. Roden
Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Journal:
Current Drug Targets
Volume:
4
Page:
113-121
Author(s):
Joachim Drevs, Michael Medinger, Carmen Schmidt-Gersbach, Renate Weber and Clemens Unger
The Prodigiosins: A New Family of Anticancer Drugs
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
57-65
Author(s):
Beatriz Montaner and Ricardo Pérez-Tomás
Cancer Chemoprevention Drug Targets
Journal:
Current Drug Targets
Volume:
4
Page:
45-54
Author(s):
K. Krishnan, S. Campbell, F. Abdel-Rahman, S. Whaley and W. L. Stone
Novel Intervention Strategies for Helicobacter pylori Treatment
Journal:
Current Drug Targets - Infectious Disorders
Volume:
2
Page:
331-338
Author(s):
Brian Noonan and Richard A. Alm
Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Journal:
Current Medicinal Chemistry - Anti-Cancer Agents
Volume:
2
Page:
691-714
Author(s):
M. Lopez-Lazaro